Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
The goal for the project is the identification and optimization of anti-viral compounds.
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
All India Institute of Ayurveda hosts ministers and showcase their achievements
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
